Norwood Abbey & AWI JV to develop needle-free delivery system
26 Aug '05
3 min read
AWI Animal Health and Welfare Program Manager Dr. Scott Williams said that preliminary trials on sheep using the needle-free prototype gave the equivalent results as conventional needle delivery.
"This is really exciting news and we are now moving into proof-of-concept trials for this particular injection device with Norwood Abbey," he added.
Following the completion of the testing and assuming all milestones are achieved, a detailed brief and proposal will be prepared for the final product development and commercialisation phase of the needle-free mulesing injector system.
Subject to the success of further trials of both the protein and applicator, the final product could be commercially available as early as 2007.
Currently surgical mulesing is performed on approximately 15 million sheep a year and has been shown to prevent 90-100% of cases of breech flystrike. However AWI has initiatives underway to develop better flystrike prevention and control, including viable alternatives to surgical mulesing.
Norwood Abbey Ltd (Norwood), headquartered in Melbourne, Australia, is a medical technology company established in 1998 to develop and commercialise medical technologies that address significant unmet medical needs. The Company has two business segments: Drug Delivery and Immunology.
In both business segments Norwood's strategy is to develop proprietary technologies protected by strong intellectual property, establish their clinical utility and then partner with pharmaceutical and medical companies to commercialise the clinical applications of the technology platforms.
marketing@alchempro.com
